Degarelix powder for solution for injection
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Injections of degarelix.
Advanced prostate cancer
Treatment of adult male patients with advanced hormone-dependent prostate cancer.
Whilst the doses stated below are those recommended by the manufacturer, local cancer network protocols for the relevant indication should be consulted.
240mg dose (as 2 x 120mg consecutive doses).
80mg (1 x 80mg dose) one month after the starting dose. Maintenance doses of 80mg should then be given monthly.
Degarelix is for subcutaneous injection only.
To be administered in the abdominal region. The injection site should be varied periodically and should be given in areas where the patient will not be exposed to pressure e.g. not close to waistband or belt and not close to the ribs.
Children under 18 years
Long QT syndrome
Torsade de pointes
Precautions and Warnings
Family history of long QT syndrome
Risk factors for cardiovascular disorder
History of torsade de pointes
Severe renal impairment
Correct electrolyte disorders before treatment
Advise ability to drive/operate machinery may be affected by side effects
For subcutaneous use only
Consider monitoring ECG in patients at risk of QT prolongation
Monitor blood glucose closely in patients with diabetes mellitus
Monitor liver function in patients with hepatic impairment
Monitor serum electrolytes
May cause loss of bone mineral density
May precipitate diabetes mellitus
Long-term clinical studies have not been including patients with confirmed or suspected hepatic disease. Mild, transient increases in ALT and AST have been observed, these were not accompanied by an increase in bilirubin or clinical symptoms.
A reduction in glucose tolerance has been observed in patients undergoing orchiectomy or in patients who have been treated with a GnRH agonist.
Development or worsening of diabetes may occur. Diabetic patients may require more frequent monitoring of blood glucose when on an androgen deprivation therapy. There are no studies about the effect of degarelix acetate on insulin and glucose levels.
Changes in bone density
A reduction in bone density has been observed in patients who have had orchiectomy or who have been treated with a GnRH agonist. It can be expected that long periods of testosterone suppression in men will have effects on bone density. During treatment with degarelix acetate, the bone density has not been evaluated.
Pregnancy and Lactation
No indicated for use in women.
No indicated for use in women.
Advise patient that side effects such as fatigue and dizziness are common and may affect the ability to drive or operate machinery.
Changes in serum calcium levels
Failure of ejaculation
Impairment of mental skills
Increase in alkaline phosphatase
Increase in plasma cholesterol
Increase of liver transaminases
Injection site reactions
Loss of libido
Prolongation of QT interval
Serum bilirubin increased
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: April 2020.
Summary of Product Characteristics: Firmagon 80mg injection. Ferring Pharmaceuticals. December 2019.
Summary of Product Characteristics: Firmagon 120mg injection. Ferring Pharmaceuticals. December 2019.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.